Results 1 to 10 of about 76,403 (315)
Pharmaceuticals, 2023 Exposure of many cancer cells, including multiple myeloma cells, to cytotoxic concentrations of natural products celastrol and withaferin A or synthetic compounds of the IHSF series resulted in denaturation of a luciferase reporter protein.
Nuria Vilaboa +6 more
doaj +1 more source
HemaSphere, 2023 Despite the recent introduction of next-generation immunotherapeutic agents, multiple myeloma (MM) remains incurable. New strategies targeting MM-specific antigens may result in a more effective therapy by preventing antigen escape, clonal evolution, and
Margaux Lejeune +12 more
doaj +1 more source
Cells, 2021 BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM).
Esperanza M. Algarín +14 more
doaj +1 more source
Scientific Reports, 2022 DNA cytosine deaminase APOBEC3B (A3B) is an endogenous source of mutations in many human cancers, including multiple myeloma. A3B proteins form catalytically inactive high molecular mass (HMM) complexes in nuclei, however, the regulatory mechanisms of ...
Yasuhiro Kazuma +14 more
doaj +1 more source
Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
Frontiers in Immunology, 2020 Previous studies showed that monoclonal immunoglobulins G (IgGs) of “monoclonal gammopathy of undetermined significance” (MGUS) and myeloma were hyposialylated, thus presumably pro-inflammatory, and for about half of patients, the target of the ...
Adrien Bosseboeuf +19 more
doaj +1 more source
Haematologica, 2018 Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138+ cell selection.
Irena Misiewicz-Krzeminska +10 more
doaj +1 more source
The serum level alterations of Acute-phase proteins, serum alpha-1-acid glycoprotein, haptoglobin and alpha-2-Macroglobulin in the Patients with Stage I of Multiple Myeloma [PDF]
Journal of Research in Applied and Basic Medical Sciences, 2020 Background & Aims: Acute phase proteins are mainly synthesized by the liver and macrophages in inflammatory conditions as a result of various traumas and malignancies.
sonya mahabadi +3 more
doaj
Frontiers in Immunology, 2022 CD38 is a target for immunotherapy of multiple myeloma. Llama-derived CD38-specific nanobodies allow easy reformatting into mono-, bi- and multispecific proteins.
Julia Hambach +10 more
doaj +1 more source
Biclonal myeloma in renal failure
Central European Journal of Immunology, 2020 Multiple myeloma is a clonal proliferation of the plasma cell line that accounts for approximately 10% of all hematological malignancies. It is characterized by abnormal growth of plasma cells producing monoclonal immunoglobulin or light chain ...
Milena K. Nikolova-Vlahova +9 more
doaj +1 more source
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Haematologica, 2011 Background To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising ...
Djordje Atanackovic +14 more
doaj +1 more source